Tag Archive for: Neuroscience

Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS

/in

Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab’s antibody discovery platform. Cambridge, UK, 9 January 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a collaboration with Lilly to discover novel […]

Read more

Vesper Bio initiates Phase Ib/IIa proof of concept study of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia (FTD)

/in

Dosing of VES001 has commenced in patients with causal gene mutations for FTD(GRN), a type of frontotemporal dementia which is invariably fatal This follows Vesper having received clinical trial authorisation from the Netherlands and the United Kingdom to initiate its Phase Ib/IIa “SORT-IN-2” trial VES001 is a first-in-class, potentially disease-modifying, orally-dosed, brain-penetrant treatment for FTD(GRN), […]

Read more

Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer

/in

Deep expertise in leading drug discovery programs across oncology, neuroscience and epigenetics Will drive advancement of Curve’s rich pipeline of first-in-class therapeutic assets Builds on recent leadership team appointments, including Andre Hoekema as Chair of the Board Southampton, UK, 9 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a […]

Read more

Alchemab advances a novel antibody with potential in Parkinson’s disease with support from The Michael J. Fox Foundation

/in

Cambridge, UK, 06 June 2024 – Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announces that it has been awarded a grant of US$595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease program. The grant will fund research performed at […]

Read more

Alchemab Therapeutics CEO to Present at Wells Fargo 2023 Healthcare Conference

/in

Cambridge, UK, September 5, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that Young Kwon, PhD, Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 2023 Healthcare Conference on 7 September 2023 at 4:30 p.m. ET. Read more…

Read more